3 Ways Coronavirus Lockdowns Put Biotech and Big Pharma on Hold

Biotech and pharmaceutical-stock investors had better strap in for some upsetting news. Efforts to slow down the rapidly spreading coronavirus so hospitals have a chance to keep up are going to affect the industry in more ways than one.

Biogen (NASDAQ: BIIB) and Eli Lilly instructed all employees to work from home whenever possible, after employees from both companies tested positive for COVID-19. Unfortunately, infected employees and work-at-home policies aren't the only disruptions facing the industry. Here's why 2020's going to be a slow year for biotech and big pharma.

Image source: Getty Images.

Continue reading

Source Fool.com